Name: Operating Profit Margin

Definition: Operating profit margin focuses on profits from the company’s core business — before interest payments and taxes. It reflects how well the business manages operating costs relative to sales. Strong operating margins show efficient day-to-day operations. Shrinking margins may reveal rising overhead, pricing weakness, or declining efficiency.

Interpretation:
• In '2021', RGEN's operating profit margin was 25.8%, highlighting profit earned from core business operations. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2021' stood at -223.0%.
• In '2022', RGEN's operating profit margin was 24.4%, highlighting profit earned from core business operations. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2022' stood at -239.5%. Industry average declined by 16.5% from previous year.
• In '2023', RGEN's operating profit margin was 2.7%, highlighting profit earned from core business operations. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at -219.0%. Industry average increased by 20.4% compared to previous year.
• In '2024', RGEN's operating profit margin was -5.0%, highlighting profit earned from core business operations. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2024' stood at -182.6%. Industry average increased by 36.4% compared to previous year.
Overall, RGEN's operating profit margin has been volatile but showed a downward trend over the past 4 years.

Formula: Operating Profit Margin = Operating Income / Revenue

Good Range: Often 10%-30% depending on business model.